Lipoprotein(a) shows substantial longitudinal variability in children with type 1 diabetes
A retrospective single-center cohort study followed 287 children and adolescents with type 1 diabetes at Geneva University Hospitals for a median of 6.2 years (IQR 2.9-9.6). The study aimed to characterize intra- and inter-individual trajectories of Lipoprotein(a) and assess implications for cardiovascular risk classification. No specific intervention or comparator was reported; the analysis focused on natural longitudinal variation.
At baseline, 26% of participants had elevated Lp(a) (≥300 mg/L). The main finding was substantial intraindividual variability: 32% of participants exhibited fluctuations exceeding 50% of their maximum Lp(a) value over time. This variability led to reclassification across the clinically relevant 300 mg/L threshold in 11.9% of the cohort. Lp(a) concentrations showed an age-related pattern, peaking between ages 10 and 13 years and declining thereafter. A modest but statistically significant seasonal variation was also observed, with higher levels in autumn and winter (P < 0.05).
Safety and tolerability data were not reported. Key limitations include the observational, single-center design, which cannot establish causality and may limit generalizability. The study did not report specific funding or conflicts of interest. For clinical practice, these findings suggest that relying on a single Lp(a) measurement in youth with type 1 diabetes may lead to misclassification of cardiovascular risk, particularly during the dynamic adolescent period when levels peak. Repeated assessment may be warranted for more accurate risk stratification.